全文获取类型
收费全文 | 310篇 |
免费 | 31篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
妇产科学 | 7篇 |
基础医学 | 45篇 |
口腔科学 | 28篇 |
临床医学 | 34篇 |
内科学 | 21篇 |
皮肤病学 | 3篇 |
神经病学 | 7篇 |
特种医学 | 10篇 |
外科学 | 31篇 |
综合类 | 24篇 |
预防医学 | 14篇 |
眼科学 | 6篇 |
药学 | 71篇 |
中国医学 | 6篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 7篇 |
2022年 | 26篇 |
2021年 | 18篇 |
2020年 | 9篇 |
2019年 | 11篇 |
2018年 | 18篇 |
2017年 | 12篇 |
2016年 | 12篇 |
2015年 | 17篇 |
2014年 | 32篇 |
2013年 | 33篇 |
2012年 | 27篇 |
2011年 | 25篇 |
2010年 | 17篇 |
2009年 | 21篇 |
2008年 | 15篇 |
2007年 | 22篇 |
2006年 | 12篇 |
2005年 | 5篇 |
2004年 | 3篇 |
2003年 | 1篇 |
2002年 | 1篇 |
2001年 | 1篇 |
2000年 | 1篇 |
排序方式: 共有346条查询结果,搜索用时 15 毫秒
341.
The transfection activity of non-viral vectors is highly dependent on the delivery capacity of the carriers. Therefore, the aim of this work was to evaluate the activity of a new PAMAM dendrimer-Transferrin conjugate (P-Tf) with improved gene delivery activity to cancer cells. The formulations containing the novel P-Tf were able to bind pDNA and protect it from the activity of DNAse I enzyme. Moreover, it formed nanoparticles with positive surface charge, although the presence of Tf led to a decrease of the zeta potential to almost electroneutral values. This new vector, formulated at N/P 6, exhibited excellent transfection efficacy in HeLa, HepG2 and CT26 cell lines, whereas in Neuro2A no improvement was achieved. Compared to control complexes with branched polyethylenimine (bPEI), targeted dendriplexes (complexes formed by cationic polymeric dendrimers and DNA) were more efficient in HepG2 and HeLa cells. Cellular viability was always kept over 80% in these cell lines with higher values than bPEI control polyplexes. The uptake via receptor-mediated endocytosis was ensured by a competition assay, by adding an excess of free Tf, which led to a decrease in the transfection activity of targeted dendriplexes. 相似文献
342.
343.
Retinal vascular diseases, including diabetic retinopathy, neovascular age related macular degeneration, and retinal vein occlusion, are leading causes of blindness in the Western world. These diseases share several common disease mechanisms, including vascular endothelial growth factor (VEGF) signaling, hypoxia, and inflammation, which provide opportunities for common therapeutic strategies. Treatment of these diseases using laser therapy, anti-VEGF injections, and/or steroids has significantly improved clinical outcomes. However, these strategies do not address the underlying root causes of pathology, and may have deleterious side effects. Furthermore, many patients continue to progress toward legal blindness despite receiving regular therapy. Nanomedicine, the engineering of therapeutics at the 1–100 nm scale, is a promising approach for improving clinical management of retinal vascular diseases. Nanomedicine-based technologies have the potential to revolutionize the treatment of ophthalmology, through enabling sustained release of drugs over several months, reducing side effects due to specific targeting of dysfunctional cells, and interfacing with currently “undruggable” targets. We will discuss emerging nanomedicine-based applications for the treatment of complications associated with retinal vascular diseases, including angiogenesis and inflammation. 相似文献
344.
随着超声医学和纳米医学的发展,超声造影技术已进入一个全新发展阶段,新材料的设计和精细纳米材料的制备进一步促进了纳米级超声造影剂的临床应用。相比传统的超声造影技术,基于纳米技术的新型超声造影剂具有生物相容性、血清稳定性和显影时间持久性等优势,纳米级超声造影剂技术在肿瘤等恶性疾病的精准诊疗一体化方面表现出令人惊喜的效果。结合笔者长期临床实践及文献报道,纳米级超声造影剂在肌肉骨骼关节领域有潜在价值,有望为相关肌肉骨骼关节疾病的诊疗及随访提供更可靠的指导。 相似文献
345.
《药学学报(英文版)》2022,12(1):92-106
Nanoparticulate drug delivery systems (Nano-DDSs) have emerged as possible solution to the obstacles of anticancer drug delivery. However, the clinical outcomes and translation are restricted by several drawbacks, such as low drug loading, premature drug leakage and carrier-related toxicity. Recently, pure drug nano-assemblies (PDNAs), fabricated by the self-assembly or co-assembly of pure drug molecules, have attracted considerable attention. Their facile and reproducible preparation technique helps to remove the bottleneck of nanomedicines including quality control, scale-up production and clinical translation. Acting as both carriers and cargos, the carrier-free PDNAs have an ultra-high or even 100% drug loading. In addition, combination therapies based on PDNAs could possibly address the most intractable problems in cancer treatment, such as tumor metastasis and drug resistance. In the present review, the latest development of PDNAs for cancer treatment is overviewed. First, PDNAs are classified according to the composition of drug molecules, and the assembly mechanisms are discussed. Furthermore, the co-delivery of PDNAs for combination therapies is summarized, with special focus on the improvement of therapeutic outcomes. Finally, future prospects and challenges of PDNAs for efficient cancer therapy are spotlighted. 相似文献
346.
《Critical reviews in oncology/hematology》2015,93(3):166-180
The application of nanotechnology in oncology has increased the efficacy and efficiency of some cytotoxic agents. The paradigm in this field is nab-paclitaxel, a soluble form of paclitaxel that is linked to albumin nanoparticles. The development of nanotechnology as a delivery system for paclitaxel has provided better pharmacokinetic and pharmacodynamic characteristics, neutralizing its hydrophobicity. This procedure significantly improves the treatment of metastatic breast cancer compared to conventional paclitaxel-based therapies, including other type of cancers such as metastatic pancreatic cancer, stage IIIB–IV non-small cell lung cancer (NSCLC) and metastatic melanoma. In these last cases, significant differences were found in primary end-points for patients treated with nab-paclitaxel-based chemotherapy compared to those treated with conventional treatments. The application of nanotechnology in cancer treatment may also improve the efficacy of other known drugs, as a result of improved pharmacokinetic and pharmacodynamic profiles, similarly to paclitaxel. 相似文献